The Buyer Pool Just Flipped: Why a Strategic — Not a PE Fund — Is Most Likely to Buy Your Behavioral Health Business in 2026

By Jacob Lynch, Managing Director, Healthcare Capital Advisors

If you've been told to expect a private-equity add-on bid for your behavioral health company, your information is a cycle out of date.

For two cycles, that was the right expectation. Sponsor-backed platforms were the most active acquirers in the lower middle market; if you ran a clean outpatient group or a mid-size addiction-treatment platform, the natural buyer was a PE-backed consolidator adding to a portfolio. Sellers were coached to build the process around that buyer, and it worked.

The data says the market has flipped. Capstone Partners' mid-year read on behavioral health M&A found that strategic acquirers accounted for more than two-thirds of deal volume in the first half of 2026, while new platform creation by sponsors was, in their word, “subdued.” In plain terms: the operators and larger companies inside your own industry are doing most of the buying right now, and the financial sponsors are waiting for the cost of debt and the exit environment to improve.

That's not a small distinction, and it changes how a smart process gets built.

It changes who you call first. A process designed for last cycle's buyer list — heavy on sponsors, light on strategics — underweights the most active buyers and leads with the least active ones. The realistic acquirer list for most assets is shorter and more strategic than it was a year ago, and discovering that in week six of a process is expensive.

It changes how you tell the story. A financial buyer underwrites an EBITDA bridge and an eventual resale. A strategic buyer underwrites fit: how your business slots into theirs, what it does for their geography or service mix, what integration looks like, what it costs to combine. A book written purely as a financial story undersells the exact thing a strategic is paying for. The integration-and-fit narrative isn't marketing for these buyers — it is the underwriting.

And it changes what “certainty to close” means. A strategic with cash on the balance sheet has a different closing profile than a sponsor assembling a debt package in a tight financing market. When two offers are close on price, the one that can actually fund is worth more than the one that can't — and in this market, that runs against the reflex that the biggest headline number always wins.

There's a flip side worth naming, because it's genuinely good news for a specific owner. Strategic appetite is real and, at the top of the market, aggressive — the multiples paid in this year's headline strategic deals confirm that thesis-driven acquirers will pay up for the right fit. If your business is the right fit for someone's stated strategy, a strategic process can produce a better outcome than a financial one, not just a more certain one.

None of this means private equity has left behavioral health. The sponsors that went quiet from 2023 through 2025 didn't disappear; they were underwriting, and when conditions turn they'll move quickly and in cash. But if you're taking a business to market in the near term, building the process around this cycle's buyer — the strategic — rather than last cycle's is one of the highest-leverage decisions you'll make. It determines who you call, what you send them, and how you weigh the offers that come back.

The box score says deal volume is moderate. The board says the buyers changed. Run your process for the buyers who are actually buying.

Not sure which buyers have a thesis that runs through your business? That's the kind of question a confidential Strategic Options Review is built to answer. — HCA

Healthcare Capital Advisors works exclusively with behavioral and mental health companies on sell-side representation, buy-side strategy, and pre-transaction readiness.  Preparation. Process. Performance.